U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Puget Sound Drug Corporation dba Key Pharmacy and Compounding Center - 552431 - 03/31/2020
  1. Warning Letters

CLOSEOUT LETTER

Puget Sound Drug Corporation dba Key Pharmacy and Compounding Center MARCS-CMS 552431 —

Delivery Method:
Via Email
Product:
Drugs

Recipient:
Recipient Name
HeeJoo Park, RPh
Recipient Title
President and CEO, COO, CFO
Puget Sound Drug Corporation dba Key Pharmacy and Compounding Center

530 South 336th Street
Federal Way, WA 98003-6383
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

19701 Fairchild
Irvine, CA 92612-2506
United States

949-608-2900

Dear Ms. Park:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL# 552431) dated April 4, 2018. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top